NCT07249879: This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Phase: PHASE1. Conditions: Relapsed/Refractory Small Cell Lung Cancer